Casey R. Ager

2.1k total citations
27 papers, 1.1k citations indexed

About

Casey R. Ager is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Casey R. Ager has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 20 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Casey R. Ager's work include Cancer Immunotherapy and Biomarkers (19 papers), Immune cells in cancer (14 papers) and Immunotherapy and Immune Responses (7 papers). Casey R. Ager is often cited by papers focused on Cancer Immunotherapy and Biomarkers (19 papers), Immune cells in cancer (14 papers) and Immunotherapy and Immune Responses (7 papers). Casey R. Ager collaborates with scholars based in United States, China and Netherlands. Casey R. Ager's co-authors include Michael A. Curran, Ashvin R. Jaiswal, Todd Bartkowiak, Matthew J. Reilley, Courtney Nicholas, Arthur Liu, Pratha Budhani, Midan Ai, Priyamvada Jayaprakash and David S. Hong and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Casey R. Ager

26 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Casey R. Ager United States 12 685 507 399 247 162 27 1.1k
Todd Bartkowiak United States 11 637 0.9× 513 1.0× 234 0.6× 194 0.8× 96 0.6× 21 963
Eileen E. Parkes United Kingdom 12 435 0.6× 541 1.1× 441 1.1× 149 0.6× 157 1.0× 36 1.0k
Jingwei Sun China 11 753 1.1× 717 1.4× 438 1.1× 109 0.4× 193 1.2× 22 1.3k
María Gato Spain 16 766 1.1× 848 1.7× 306 0.8× 116 0.5× 147 0.9× 23 1.3k
María Villalba Spain 20 341 0.5× 366 0.7× 407 1.0× 232 0.9× 143 0.9× 35 959
Agata Cova Italy 12 571 0.8× 320 0.6× 664 1.7× 422 1.7× 101 0.6× 24 1.2k
Aixa Soyano United States 9 482 0.7× 713 1.4× 234 0.6× 110 0.4× 229 1.4× 30 1.1k
Miren Zuazo Spain 17 760 1.1× 1.0k 2.0× 296 0.7× 123 0.5× 195 1.2× 27 1.4k
Boxuan Zhou China 14 717 1.0× 438 0.9× 521 1.3× 299 1.2× 173 1.1× 40 1.4k
Meisi Yan China 13 538 0.8× 553 1.1× 600 1.5× 305 1.2× 281 1.7× 21 1.2k

Countries citing papers authored by Casey R. Ager

Since Specialization
Citations

This map shows the geographic impact of Casey R. Ager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Casey R. Ager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Casey R. Ager more than expected).

Fields of papers citing papers by Casey R. Ager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Casey R. Ager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Casey R. Ager. The network helps show where Casey R. Ager may publish in the future.

Co-authorship network of co-authors of Casey R. Ager

This figure shows the co-authorship network connecting the top 25 collaborators of Casey R. Ager. A scholar is included among the top collaborators of Casey R. Ager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Casey R. Ager. Casey R. Ager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gouda, Mohamed A., Matthew J. Reilley, Amadeo B. Biter, et al.. (2025). Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial. PubMed. 8(2). 89–98. 1 indexed citations
2.
Liu, Arthur, Jeffrey J. Molldrem, Gheath Alatrash, et al.. (2024). Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia. Cancer Research Communications. 4(3). 911–918. 1 indexed citations
3.
Liu, Arthur, Seth T. Gammon, Federica Pisaneschi, et al.. (2023). Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight. 9(1). 7 indexed citations
4.
Ager, Casey R., Mingxuan Zhang, Matthew G. Chaimowitz, et al.. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer. 11(9). e006782–e006782. 7 indexed citations
5.
6.
7.
Obradović, Aleksandar, Nivedita Chowdhury, Scott M. Haake, et al.. (2021). Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 184(11). 2988–3005.e16. 191 indexed citations
8.
Ager, Casey R., Aleksandar Obradović, Juan Martín Arriaga, et al.. (2021). Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model. Cancer Immunology Research. 9(5). 529–541. 10 indexed citations
9.
Ager, Casey R., Kimal Rajapakshe, Maria Emilia Di Francesco, et al.. (2021). High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Journal for ImmunoTherapy of Cancer. 9(8). e003246–e003246. 47 indexed citations
10.
11.
Jaiswal, Ashvin R., Arthur Liu, Shivanand Pudakalakatti, et al.. (2020). Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research. 8(11). 1365–1380. 43 indexed citations
12.
Aggen, David H., Casey R. Ager, Aleksandar Obradović, et al.. (2020). Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clinical Cancer Research. 27(2). 608–621. 92 indexed citations
13.
Reilley, Matthew J., et al.. (2019). TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. Journal for ImmunoTherapy of Cancer. 7(1). 323–323. 64 indexed citations
14.
Ager, Casey R., et al.. (2019). Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorganic & Medicinal Chemistry Letters. 29(20). 126640–126640. 35 indexed citations
15.
Ager, Casey R., Maria Emilia Di Francesco, Philip Jones, & Michael A. Curran. (2019). Abstract A050: Intratumoral delivery of a novel STING agonist synergizes with checkpoint blockade to regress multifocal pancreatic cancer. Cancer Immunology Research. 7(2_Supplement). A050–A050. 2 indexed citations
16.
Bartkowiak, Todd, Ashvin R. Jaiswal, Casey R. Ager, et al.. (2018). Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway. Clinical Cancer Research. 24(5). 1138–1151. 70 indexed citations
17.
Jayaprakash, Priyamvada, Midan Ai, Arthur Liu, et al.. (2018). Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. Journal of Clinical Investigation. 128(11). 5137–5149. 305 indexed citations
18.
Ager, Casey R., Matthew J. Reilley, Courtney Nicholas, et al.. (2017). Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Cancer Immunology Research. 5(8). 676–684. 146 indexed citations
19.
Bartkowiak, Todd, Ashvin R. Jaiswal, Midan Ai, et al.. (2016). Mechanisms underlying 4-1BB agonist antibody mediated hepatotoxicity. The Journal of Immunology. 196(1_Supplement). 188.5–188.5. 2 indexed citations
20.
Harger, Matthew, Casey R. Ager, David M. Zong, et al.. (2012). Expanding the Product Profile of a Microbial Alkane Biosynthetic Pathway. ACS Synthetic Biology. 2(1). 59–62. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Todd Bartkowiak Breakdown of academic impact, for papers by Eileen E. Parkes Breakdown of academic impact, for papers by Jingwei Sun Breakdown of academic impact, for papers by María Gato Breakdown of academic impact, for papers by María Villalba Breakdown of academic impact, for papers by Agata Cova Breakdown of academic impact, for papers by Aixa Soyano Breakdown of academic impact, for papers by Miren Zuazo Breakdown of academic impact, for papers by Boxuan Zhou Breakdown of academic impact, for papers by Meisi Yan
Rankless by CCL
2026